Table 2.
Association between baseline characteristics and drug exposures with K65/66K for members of the HOMER cohort. Participants initiated treatment between August 1, 1996 and November 30, 2005.
| Variable | Subcategory | Presence of 65K and/or 66K silent Mutation (N [%])
|
||
|---|---|---|---|---|
| No | Yes | p-Value | ||
| Gender | Male | 1531 (80.1) | 548 (87.0) | <0.001 |
| Female | 381 (19.9) | 82 (13.0) | ||
| AIDS Diagnosis | Yes | 264 (13.8) | 103(16.4) | 0.12 |
| No | 1648 (86.2) | 527 (83.7) | ||
| History of Injection Drug Use | Yes | 693 (36.2) | 186 (29.5) | 0.0021 |
| No | 1219 (63.8) | 444 (70.5) | ||
| Year of First Therapy | 1996 – 1999 | 1104 (57.7) | 367 (58.3) | 0.83 |
| 1999 – 2003 | 616 (32.2) | 196 (31.1) | ||
| 2003 – 2005 | 192 (10.0) | 67 (10.6) | ||
| Adherence | 0% – <40% | 355 (18.7) | 104 (16.6) | 0.066 |
| 40% – <80% | 459 (24.2) | 127 (20.3) | ||
| 80% – <95% | 281 (14.8) | 104 (16.6) | ||
| ≥95% | 804 (42.3) | 292 (46.6) | ||
| CD4+ Cell Count (cells/mm3) | <200 | 766 (40.5) | 295 (47.12) | 0.015 |
| 200 – <350 | 528 (27.9) | 155 (24.76) | ||
| ≥350 | 597 (31.6) | 176 (28.12) | ||
| Plasma Viral Load (log10) | <4 | 131 (7.9) | 43 (8.3) | 0.95 |
| 4 – <5 | 627 (37.7) | 195 (37.7) | ||
| ≥5 | 904 (54.4) | 279 (54.0) | ||
| Antiretroviral Drug Exposure | Lamivudine | 1801 (94.2) | 599 (95.1) | 0.40 |
| Abacavir | 308 (16.1) | 157 (24.9) | <0.001 | |
| Zidovudine | 1091 (57.1) | 359 (57.0) | 0.97 | |
| Stavudine | 1210 (63.3) | 444 (70.5) | 0.001 | |
| Zalcitabine | 67 (3.5) | 31 (4.9) | 0.11 | |
| Didanosine | 742 (38.8) | 286 (45.4) | 0.0035 | |
| Tenofovir | 271 (14.2) | 130 (20.6) | <0.001 | |